ReviewNutrients2018
Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease.
Review in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Approach to anaemia in gastrointestinal disease: A position paper by the ESPGHAN Gastroenterology Committee.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Diet and inflammatory bowel disease: The Asian Working Group guidelines.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Guideline
- Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.Inflammatory bowel diseases · 2022Trial
- Anemia of Chronic Disease: Pathophysiology, Diagnosis and Management.Hematology reports · 2026Review
- Iron metabolism and ferroptosis in human health and disease.BMC biology · 2025Review
- Advances in Iron Deficiency Anaemia Management: Exploring Novel Drug Delivery Systems and Future Perspectives.Current drug delivery · 2025Review
- Anemia of Inflammation.Advances in experimental medicine and biology · 2025Review
- Review
- Oral iron supplementation: new formulations, old questions.Haematologica · 2024Review
- Nutritional Aspects of Iron in Health and Disease.Nutrients · 2023Review
- Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary center: A retrospective observational cohort study.World journal of clinical cases · 2023Article
- Adjunctive therapeutic effects of micronutrient supplementation in inflammatory bowel disease.Frontiers in immunology · 2023Review
- Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action.Journal of internal medicine · 2022Review
- Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease.Medicine · 2022Article
- Review
- Supplementation with High or Low Iron Reduces Colitis Severity in an AOM/DSS Mouse Model.Nutrients · 2022Article
- Iron-Induced Hepatocarcinogenesis-Preventive Effects of Nutrients.Frontiers in oncology · 2022Review
- Review
- Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.Nutrients · 2021Review
- Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaemia is the most frequent, though often neglected, comorbidity of inflammatory bowel disease (IBD). Here we want to briefly present (1) the burden of anaemia in IBD, (2) its pathophysiology, which mostly arises from bleeding-associated iron deficiency, followed by (3) diagnostic evaluation of anaemia, (4) a balanced overview of the different modes of iron replacement therapy, (5) evidence for their therapeutic efficacy and subsequently, (6) an updated recommendation for the practical management of anaemia in IBD. Following the introduction of various intravenous iron preparations over the last decade, questions persist about when to use these preparations as opposed to traditional and other novel oral iron therapeutic agents. At present, oral iron therapy is generally preferred for patients with quiescent IBD and mild iron-deficiency anaemia. However, in patients with flaring IBD that hampers intestinal iron absorption and in those with inadequate responses to or side effects with oral preparations, intravenous iron supplementation is the therapy of choice, although information on the efficacy of intravenous iron in patients with active IBD and anaemia is scare. Importantly, anaemia in IBD is often multifactorial and a careful diagnostic workup is mandatory for optimized treatment. Nevertheless, limited information is available on optimal therapeutic start and end points for treatment of anaemia. Of note, neither oral nor intravenous therapies seem to exacerbate the clinical course of IBD. However, additional prospective studies are still warranted to determine the optimal therapy in complex conditions such as IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.